BriaCell Therapeutics (TSE:BCT) has released an update.
BriaCell Therapeutics has successfully closed a $5.5 million public offering, selling 7.4 million common shares and accompanying warrants. The company plans to allocate the proceeds toward working capital, corporate purposes, and advancing its business goals. ThinkEquity served as the sole book-running manager for this offering.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.